Tanya Simuni MD, FAAN
Arthur C. Nielsen Professor of Neurology; Director, Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IllinoisDr. Simuni joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region.
She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees for PSG and the PF. She is the Site PI and Steering Committee member for the largest PD biomarker initiative (PPMI study) and site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT). Dr. Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the Parkinson’s Study Group.
Disclosures
As of April 2, 2024:In the last 12 months, Tanya Simuni, MD, has served as a consultant for AskBio, Amneal, Blue Rock Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, General Electric, Kyowa, Neuroderm/ MTPA, Prevail/ Lilly, Roche, Sanofi, Sinopia, Takeda and Vanqua Bio. Dr. Simuni served on the ad board for AskBio, Amneal, Biohaven, Denali, GAIN, General Electric, Kyowa, MJFF, Neuron23, Parkinson Study Group, Prevail/ Lilly, and Roche. Dr. Simuni has served as a member of the scientific advisory board of Koneksa, Neuroderm/ MTPA, Sanofi and UCB. Dr. Simuni has received research funding from Amneal, Biogen, Neuroderm, Prevail, Roche, UCB and is an investigator for NINDS, MJFF, Parkinson’s Foundation.
Dr. Simuni has no relevant disclosures related to her work for PracticeUpdate.